IVIX.F Stock Overview
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Invion Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.005 |
| 52 Week High | AU$0.005 |
| 52 Week Low | AU$0.0032 |
| Beta | 1.2 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -5.66% |
| 5 Year Change | n/a |
| Change since IPO | -91.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVIX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -1.7% |
| 1Y | n/a | 14.6% | 22.9% |
Return vs Industry: Insufficient data to determine how IVIX.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IVIX.F performed against the US Market.
Price Volatility
| IVIX.F volatility | |
|---|---|
| IVIX.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IVIX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IVIX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Thian Chew | www.inviongroup.com |
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.
Invion Limited Fundamentals Summary
| IVIX.F fundamental statistics | |
|---|---|
| Market cap | US$20.98m |
| Earnings (TTM) | -US$978.51k |
| Revenue (TTM) | US$2.87m |
7.3x
P/S Ratio-21.4x
P/E RatioIs IVIX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVIX.F income statement (TTM) | |
|---|---|
| Revenue | AU$4.39m |
| Cost of Revenue | AU$3.01m |
| Gross Profit | AU$1.38m |
| Other Expenses | AU$2.88m |
| Earnings | -AU$1.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00023 |
| Gross Margin | 31.43% |
| Net Profit Margin | -34.15% |
| Debt/Equity Ratio | 0% |
How did IVIX.F perform over the long term?
See historical performance and comparison